BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25073741)

  • 1. Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network.
    Sardiu ME; Smith KT; Groppe BD; Gilmore JM; Saraf A; Egidy R; Peak A; Seidel CW; Florens L; Workman JL; Washburn MP
    Mol Cell Proteomics; 2014 Nov; 13(11):3114-25. PubMed ID: 25073741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.
    Smith KT; Martin-Brown SA; Florens L; Washburn MP; Workman JL
    Chem Biol; 2010 Jan; 17(1):65-74. PubMed ID: 20142042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
    Tambunan US; Bramantya N; Parikesit AA
    BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
    Choi SE; Weerasinghe SV; Pflum MK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.
    Jin JS; Tsao TY; Sun PC; Yu CP; Tzao C
    Pathol Oncol Res; 2012 Jul; 18(3):713-20. PubMed ID: 22270866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
    Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
    Zhou X; Yang XY; Popescu NC
    Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
    Hutt DM; Roth DM; Vignaud H; Cullin C; Bouchecareilh M
    PLoS One; 2014; 9(8):e106224. PubMed ID: 25166596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
    Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
    Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
    Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
    Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
    Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
    Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
    Yerbes R; López-Rivas A
    Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.